Cancer is one of the most fatal and chronic disorders in which, there is development of tumors due to uncontrolled growth of cells of particular part of the body. Cancer is highly hazardous disease in which the mortality rate is extremely high due to highly invasive nature and prolonged duration of disease.
Anaplastic thyroid cancer (ATC) is the most lethal type of thyroid cancer. In this disease, the tissues of thyroid start growing in an aggressive and uncontrollable manner. This growth is usually malignant and rapidly invades surrounding tissues, such as trachea and epiglottis. The prognosis of thyroid cancer is highly difficult and the rate is less than 5% of the total number of incidences. However, some of the symptoms shown by ATC in the metastasis stage include chronic cough with blood, loud breathing, changes in voice and others. The diagnosis of the disease is carried out by using some imaging studies, such as CT scan, MRI, and PET scanning. Needle aspiration biopsy test is also used for diagnosis and confirmation of the disease.
The market of anaplastic thyroid cancer is segmented on the basis of pipeline products, such as MLN0128 (phase 2), crolibulin (phase 1), CS7017 (phase 1), paclitaxel and pazopanib HCl (phase 2), CA4P (phase 2), bevacizumab (phase 2), sorafenib (phase 2), lapatinib ditosylate and dabrafenib (phase 1), everolimus (phase 2), cabozantinib (phase 2) and many others. Further, the market is also segmented on the basis of types of treatments available, such as radiation therapy, chemotherapy, cryosurgery and surgical treatments. In radiation therapy, high energy X-rays or gamma-rays are used to destroy the tumor. Chemotherapy is pharmacological treatment by using anti-cancer drugs either orally or parenterally. Major drugs include strontium-89 chloride, methotrexate, denosumab, doxorubicin and many others. Cryosurgery is also sometimes used to treat anaplastic thyroid cancer; however its usage rate is negligible. Tracheotomy and the complete thyroidectomy are the major surgeries used to treat ATC. Although various treatment alternatives are available in the market, mortality rate of the disease is very high, mainly due to poor prognosis. In addition, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). The North American region is the most dominating market in the world, owing to steadily growing incidences of anaplastic thyroid cancer and rising focus towards R&D for ATC treatments. On the other hand, Asia-Pacific and RoW regions are the most promising markets in the upcoming period, owing to rise in awareness of thyroid cancer, its chronic impacts and its treatments and rapid development in medical infrastructure.
The market of anaplastic thyroid cancer is expected to witness steady growth rate during the forecast period from 2014 to 2020. This growth is anticipated to drive by various factors, such as R&D practices running across the globe, rising awareness amongst the population for thyroid cancer, increasing medical infrastructure and technological advancements. Owing to R&D practices, a number of drugs and formulations are under pipeline studies and are expected to enter in the market during the forecast period. The major pipeline drugs are bevacizumab, sorafenib, everolimus, cabozantinib and others. However, low prevalence of the disease is the major hurdle in the market growth, followed by high cost of R&D, diagnosis and treatment. According to the statistics provided by the U.S. National Library of Medicine and the National Institute of Health, anaplastic thyroid cancer accounts for approximately 1% of the all thyroid cancer cases, which is very less compared to other types of cancer. Hence, this very low prevalence is the major hurdle in the market growth.
The major players operating in this market include GlaxoSmithKline plc, OXiGENE, Inc., Daichi Sankyo Company Limited, Immune Pharmaceuticals, Inc., and Exelixis, Inc. amongst others.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.